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The challenge of risk estimation in
cardiovascular prevention
Thomas F. Lu¨scher, MD, FESC
Editor-in-Chief, Zurich Heart House, Careum Campus, Moussonstrasse 4, 8091 Zurich, Switzerland
Prevention received a lot of attention during the last year. Not only
were the ESC/EAS Guidelines on Prevention1 and the Joint ESC/EAS
Guidelines for the Management of Dyslipidaemias2 published, but novel
and most promising drugs for lipid disorders3–5 and diabetes6,7 were
evaluated and discussed. Massimo F. Piepoli and colleagues from G. da
Saliceto Hospital in Piacenza, Italy summarize in their review ‘The year
in cardiology 2016: prevention’8 the recent insights which have be-
come available in the complex interaction between prevention and risk
factor control. This includes healthy lifestyle, diet, smoking habit, obes-
ity, diabetes, lipids, and hypertension. Furthermore, the pivotal role of
environmental stressors such as noise and pollution is highlighted. Of
the utmost importance was the introduction of novel, highly promising
drugs such as the PCSK9 (proprotein convertase subtilisin/kexin type
9) inhibitors for patients with hyperlipidaemia and of the inhibitors of
the sodium–glucose exchanger for patients with diabetes.
An important novel topic in prevention is highlighted by Thomas
Mu¨nzel and colleagues from the Johannes Gutenberg University in
Mainz, Germany in a subsequent two-part clinical review article enti-
tled ‘Environmental stressors and cardio-metabolic dis-
ease’.9,10 The authors note that traffic noise11 and air pollution
together represent the two most important environmental risk fac-
tors in urbanized societies. The first of this two-part review discusses
the epidemiological evidence in support of the existence of an associ-
ation between these risk factors and cardiovascular and metabolic dis-
ease, as well as Tako Tsubo.12 While independent effects of these risk
factors have now clearly been shown, recent studies also suggest that
the two exposures may interact with each other, and also with trad-
itional risk factors such as hypertension and type 2 diabetes. From a
societal and policy perspective, the health effects of both air pollution
and traffic noise are observed for exposures well below the thresh-
olds currently accepted as being safe. Current gaps in knowledge, ef-
fects of intervention, and their impact on cardiovascular disease are
discussed in the second part of this review. Increased awareness of
the societal burden posed by these novel risk factors and acknow-
ledgement in traditional risk factor guidelines may intensify the efforts
required for effective legislation to reduce air pollution and noise.
The novel PCSK9 inhibitors are both effective and expensive. Thus,
their prescription must be considered by weighing costs and bene-
fits.13 In most countries, however, the cost of these drugs is only
reimbursed for patients with familial hypercholesterolaemia. Hence,
genetic testing in such individuals has become important. Joost
Besseling and colleagues from the Academic Medical Center in
Amsterdam, The Netherlands address this issue in their manuscript
‘Selection of individuals for genetic testing for familial hyper-
cholesterolaemia: development and external validation of a
prediction model for the presence of a mutation causing fa-
milial hypercholesterolaemia’.14 The authors remind us that fa-
milial hypercholesterolaemia is an autosomal dominant disease that
warrants early diagnosis to prevent premature cardiovascular disease.
Genetic testing to make a definite diagnosis is costly, and careful selec-
tion of eligible subjects is important. Unfortunately, accuracy of cur-
rent diagnostic criteria is poor, especially in young individuals. The
authors therefore developed and validated a model to predict the
presence of familial hypercholesterolaemia-causing mutations in per-
sons referred by general practitioners. All participants in the Dutch fa-
milial hypercholesterolaemia screening programme from 1994 to
2014 were included in the development cohort. The validation cohort
consisted of consecutive patients suspected of familial hypercholes-
terolaemia who were attending the outpatient lipid clinic in Saguenay
in Quebec between 1993 and 2014. Cross-sectional data were avail-
able on medical history, lipid profile, and DNA analysis. Multivariable
logistic regression analysis was used for model development. The pri-
mary outcome was the presence of a deleterious familial hypercholes-
terolaemia mutation. The development cohort comprised 26 167
familial hypercholesterolaemia patients and 37 939 unaffected rela-
tives. The author’s final model included age, gender, levels of LDL-
cholesterol, HDL-cholesterol, and triglycerides, history and age of
onset of cardiovascular disease, use of statins, smoking, alcohol, and
presence of hypertension. The area under the receiver operating
characteristic curve or AUC was 85%. The calibration slope was 1.02
(where 1.00 is optimal). In the validation cohort consisting of 1436 fa-
milial hypercholesterolaemia patients and 1767 unaffected individuals,
the AUC was 95% and the calibration slope 1.06. The authors there-
fore conclude that their model allows for good discrimination and
calibration and hence may be of particular added value for the predic-
tion of a genetic mutation in young individuals. Their findings are
discussed in a thought-provoking Editorial by Marina Cuchel from
the University of Pennsylvania, USA.15
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..While the untoward effects of cardiometabolic risk factors on the
heart and the peripheral circulation are well established, their effects
on the brain and in particular on cognitive function are less well char-
acterized, although in heart failure cognitive impairment seems to
be associated with outcome.16 In their manuscript entitled
‘Associations between single and multiple cardiometabolic
diseases and cognitive abilities in 474 129 UK Biobank par-
ticipants’,17 Donald Lyall and colleagues from the University of
Glasgow in the UK investigated this aspect. Indeed, cardiometabolic
diseases such as hypertension, coronary artery disease, and type 2
diabetes are known to associate with poorer cognitive ability but
there are limited data on whether having more than one of these
conditions is associated with additive effects. The authors aimed to
quantify the magnitude of their associations with non-demented
cognitive abilities, and to determine the extent to which these associ-
ations were additive. To that end, they obtained cognitive test scores
in domains of reasoning, information processing speed, and memory,
included as part of the baseline UK Biobank cohort assessment in
474 129 individuals and adjusted for a range of potentially confound-
ing variables. Hypertension, coronary artery disease, and type 2 dia-
betes was generally associated with poorer cognitive scores on all
tests, compared with a control group that reported none of these
diseases. There was evidence of an additive deleterious dose effect of
an increasing number of cardiometabolic diseases, for reasoning
scores and log memory errors. The authors therefore concluded
that cardiometabolic diseases are associated with worse cognitive
abilities, and the effect of an increasing number of cardiometabolic
conditions appears additive. These results reinforce the notion that
Figure 1 Calibration comparing observed and predicted events in 40- to 75-year-old individuals in the Copenhagen General Population Study. US
PCE performed well below 10% any atherosclerotic cardiovascular disease 10-year risk, with good calibration around the guideline-defined decision
thresholds of 5% and 7.5% for statin therapy (left panel). In contrast, European SCORE overestimated risk across all deciles and categories of fatal ath-
erosclerotic cardiovascular disease 10-year predicted risk, with substantial overestimation around both the high-risk (5%) and very-high-risk (10%)
thresholds for statin therapy (right panel). Observed events were Kaplan–Meier adjusted. Error bars indicate 95% confidence interval. PCE, pooled
cohort equations; SCORE, SystematicCOronary Risk Evaluation. (from Mortensen MB, Nordestgaard BG, Afzal S, Falk E. ACC/AHA guidelines su-
perior to ESC/EAS guidelines for primary prevention with statins in non-diabetic Europeans: the Copenhagen General Population Study. See pages
586–594.)
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.. preventing or delaying cardiovascular disease or diabetes may also
delay cognitive decline and possibly dementia. These clinically import-
ant findings are put into context in an Editorial authored by Jack de
la Torre from the University of Texas at Austin, USA.18
Risk scores are essential tools in the prevention of cardiovascular
disease and the basis of many guideline recommendations. To that
end, a large number of scores have been developed by different pro-
fessional societies. Rarely have they been evaluated head-to-head to
determine their true clinical value. In their research article, ‘ACC/
AHA guidelines superior to ESC/EAS guidelines for pri-
mary prevention with statins in non-diabetic Europeans:
the Copenhagen General Population Study’,19 Børge Grønne
Nordestgaard and colleagues from the Herlev University Hospital in
Denmark compared the 2013 American College of Cardiology/
American Heart Association or ACC/AHA20 and the 2012 European
Society of Cardiology/European Atherosclerosis Society or ESC/EAS
guidelines on prevention of atherosclerotic cardiovascular disease21
using different risk prediction models such as the US Pooled Cohort
Equations or US-PCE, a score predicting any event, and the European
Systematic COronary Risk Evaluation system or European-SCORE
that predicts only fatal events and different statin eligibility criteria.
The authors examined 44 889 individuals aged 40–75 recruited in the
Copenhagen General Population Study, all free of cardiovascular dis-
ease and diabetes, and off statin use at baseline. They detected 2217
atherosclerotic cardiovascular events and 199 fatal events. The
predicted-to-observed event ratio was 1.2 using US-PCE for any
event and 5.0 using European-SCORE for fatal events. The US-PCE,
but not the European-SCORE, was well calibrated around decision
thresholds for statin therapy (Figure 1). Indeed, for a class I recom-
mendation, 42% of individuals qualified for statins using the ACC/
AHA guidelines, but only 6% using the ESC/EAS guidelines. Using
ACC/AHA- vs. ESC/EAS-defined statin eligibility criteria led to a sub-
stantial gain in sensitivity of 62% for any event and 76% for fatal
events, with a smaller loss in specificity of 35% for any and 36% for
fatal atherosclerotic events. Similar differences between the ACC/
AHA and ESC/EAS guidelines were found for men and women separ-
ately, and for class IIa recommendations. The sensitivity and specifi-
city of a US-PCE risk of 5% were similar to those of a European-
SCORE risk of 1.4%, while a US-PCE risk of 7.5% was similar to a
European-SCORE risk of 2.4% (Figure 2). Nordestgaard and collegues
conclude that the ACC/AHA guidelines were superior to the ESC/
EAS guidelines for primary prevention of atherosclerotic cardiovas-
cular disease, specifically for assigning statin therapy to those who
would benefit the most. These provocative findings are put into per-
spective in an Editorial by John J.P. Kastelein from the University of
Amsterdam in The Netherlands.22
This approach is further refined in a final research article ‘Risk
score overestimation: the impact of individual cardiovascu-
lar risk factors and preventive therapies on the perform-
ance of the AHA-ACC-ASCVD risk scores in a modern
Figure 2 Observed atherosclerotic cardiovascular disease per-
centage and American Heart Association-American College of
Cardiology-Atherosclerotic Cardiovascular Disease risk score pre-
dicted percentage. *P-value of ,0.05 for proportion test comparing
American Heart Association-American College of Cardiology-
Atherosclerotic Cardiovascular Disease predicted risk (total height of
each bar) with the observed risk in Multi-Ethnic Study of
Atherosclerosis (grey portion of bars). For example, the American
Heart Association-American College of Cardiology-Atherosclerotic
Cardiovascular Disease predicted risk for men was 13.9%, whereas
the observed rate was 7.2%, and a two-tailed test of proportions
showed these rates were significantly different at the 95% level.
Reported P-value compares the overestimation (i.e. the black bars)
for each risk factor. For example, the American Heart Association-
American College of Cardiology-Atherosclerotic Cardiovascular
Disease predicted risk (total height of each bar) was higher than the
observed risk (grey portion of the bar) for females and for males, and
the overestimation for males was significantly greater (P , 0.001) than
the overestimation for females. P-values come from an absolute risk
regression model, which is a linear regression model at the individual
level, predicting a dichotomous outcome (atherosclerotic cardiovas-
cular disease event yes/no within 10 years). It was fit as a generalized
linear model with the American Heart Association-American College
of Cardiology-Atherosclerotic Cardiovascular Disease risk score
entered as an offset (fixing the coefficient to 1.0), with an identity link
function and using robust standard errors. To this model, we added
each risk factor separately. P-value for race/ethnicity categories shows
joint F-test of significance. (from DeFilippis AP, Young R, McEvoy
JW, Michos ED, Sandfort V, Kronmal RA, McClelland RL, Blaha MJ.
Risk score overestimation: the impact of individual cardiovascular risk
factors and preventive therapies on the performance of the American
Heart Association-American College of Cardiology-Atherosclerotic
Cardiovascular Disease risk score in a modern multi-ethnic cohort.
See pages 598–608.)
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..multiethnic cohort’ by Andrew Paul DeFilippis and colleagues
from the University of Louisville in Kentucky, USA.23 The authors
evaluated the 2013 American Heart Association (AHA)–American
College of Cardiology (ACC)-Atherosclerotic Cardiovascular
Disease or ASCVD risk score among different race or ethnic groups,
specifically to ascertain which factors are most associated with risk
overestimation by the AHA-ACC-ASCVD scores. The Multi-Ethnic
Study of Atherosclerosis, called MESA, a prospective community-
based cohort, was used to examine calibration and discrimination of
the AHA-ACC-ASCVD risk score in 6441 White, Black, Chinese,
and Hispanic Americans, aged 45–79 years, free of known cardiovas-
cular disease at baseline. Overestimation of risk was observed in all
race and ethnic groups in MESA and was highest among Chinese,
with 252% for women and 314% for men and lowest in White
women with 72% and Hispanic men with 67% overestimation, re-
spectively. Higher age, Chinese ethnicity as compared with Whites,
systolic blood pressure, regardless of whether treated or untreated,
diabetes, alcohol use, exercise, lipid-lowering medication, and aspirin
use were all associated with a greater risk overestimation, while fam-
ily history was associated with less. The authors conclude that the
AHA-ACC-ASCVD risk score overestimates atherosclerotic cardio-
vascular risk among men, women, and in all four race or ethnic
groups evaluated in a modern US primary prevention cohort.
Clinicians treating patients similar to those in MESA, particularly older
individuals and those with factors associated with more risk overesti-
mation, should therefore consider interpreting absolute ASCVD risk
estimates with caution.
The editors hope that readers of this issue of the European Heart
Journal will find it of interest.
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